Your strain's output is the ceiling. We raise it — without genetic modification.

Yes. Confidentiality is the starting point of every project at Deltra Labs, not an afterthought. We sign a mutual non-disclosure agreement before any technical discussion begins — this includes before you share strain identity, organism source, fermentation performance data, process parameters, screening results, or any business context. If you prefer to have a signed NDA in place before even the first exploratory call, that is not a problem. We sign first, then talk.All results, process data, fermentation protocols, mutagenesis records, screening data, pedigree documentation, and intellectual property generated during your project are fully and exclusively yours. Deltra Labs retains no rights, licences, or claims to any project output — including intermediate improved strains generated during the campaign that you choose to retain alongside the final improved variant. The assignment of intellectual property is documented explicitly in the project agreement before any work begins, so there is no ambiguity at project close.Your organisms are handled in dedicated containment that is physically separated from other client work at all times. Strains are stored, cultured, and processed in designated areas with no cross-contamination risk and no co-mingling with other client biological material. All project data, experimental results, analytical records, and correspondence are stored securely and are never shared with third parties, subcontractors, or academic collaborators without your explicit written consent.Biological material handling at project close follows your instructions. All strains, cultures, glycerol stocks, and intermediate samples belonging to you are returned to you directly, transferred to a long-term strain storage facility of your choice such as a DSMZ deposit or internal culture collection, or destroyed by autoclave with a destruction certificate provided upon request. We do not retain copies of your strains or working cultures after project close unless you explicitly request that we do so as part of a strain banking arrangement.For clients working in sensitive sectors — speciality enzymes, food and feed ingredients, pharmaceutical fermentation, fine chemicals, or bio-based materials — we are experienced in working under the confidentiality and data governance standards those industries require, including alignment with internal quality management systems and third-party audit requirements. If your organisation requires a specific NDA format, supplier confidentiality agreement, or quality system document as a condition of engagement, send it to us before the intro call and we will review it.The mutual NDA covers both parties symmetrically and remains in force for the full contractual term, typically five years from the project close date, unless a longer term is required by the nature of the project or the regulatory context of your product.

Yes. Strains developed through classical mutagenesis and selection contain no recombinant DNA, no foreign genetic material, and no targeted genetic edits. Under EU Directive 2001/18/EC, organisms produced by classical mutagenesis techniques — including UV irradiation and chemical mutagenesis — are explicitly exempted from GMO classification, provided no recombinant nucleic acid molecules or genetically modified organisms are used in the process. The same principle applies under FDA guidelines for food and feed applications in the United States. This regulatory status is not a grey area — it is a well-established exemption with decades of regulatory precedent, and it is precisely why classical strain improvement remains the method of choice for food, feed, pharma, and industrial applications where GMO classification would create a commercial or regulatory barrier. Deltra Labs delivers the strain pedigree documentation needed to demonstrate and defend this non-GMO status to regulators, quality departments, and customers.

Plateaus are a normal part of classical strain improvement, they occur when the most accessible beneficial mutations in a population have already been selected, and further improvement requires either a different mutagenesis strategy, a different selection pressure, or a different screening approach. Go/no-go milestones are written into every Deltra Labs project contract. At each milestone you receive the current performance data and a recommendation on whether to continue, adjust the strategy, or close the project. You are never obligated to proceed to the next phase. If a plateau is reached and we believe a different approach could break through it, we will say so explicitly and propose an adjusted strategy with a revised scope. If we believe further improvement is unlikely to be cost-effective, we will say that too. Our goal is to give you an honest assessment at every stage, not to extend a project beyond its productive window.

Yes. Deltra Labs delivers complete strain pedigree documentation as a standard part of every project, not as an optional add-on. The pedigree document includes the identity and source of the starting strain, every mutagenesis treatment applied with full conditions (mutagen type, concentration or dose, exposure time, survival rate), the selection criteria and screening methodology used at each round, the lineage of selected colonies, stability testing results showing that the improved phenotype is maintained over successive generations, and final strain characterisation data. This documentation is formatted to support GRAS (Generally Recognized As Safe) notifications to the FDA, AMF dossiers, EU novel food applications, and internal quality assurance requirements at industrial companies. If your submission has specific formatting requirements from a regulatory body or internal QA team, we can align our documentation format to those requirements at the start of the project.

Campaign length depends on four main factors: the organism, the target phenotype, the number of mutagenesis and selection rounds required, and the availability of a high-throughput screening method for the targeted phenotype. This last factor is often decisive - and it varies significantly between projects. When a reliable, rapid screening assay exists for the target trait, large mutant populations can be evaluated quickly and the campaign moves fast. When no such assay exists, or when the target phenotype can only be measured through time-consuming fermentation runs, the screening step becomes the bottleneck and the timeline extends accordingly. Developing or adapting a suitable screening strategy is therefore one of the first things we address in the project proposal.As a general guide: a focused single-trait campaign targeting titer improvement in a fast-growing bacterial strain such as E. coli or Corynebacterium typically runs 8 to 14 weeks from project start to final data delivery, assuming a straightforward screening assay is available. Campaigns involving yeasts typically run 10 to 16 weeks due to longer generation times. Campaigns targeting filamentous fungi, which have significantly longer growth cycles on agar and in liquid culture, typically run 16 to 24 weeks. Campaigns that combine multiple mutagenesis strategies — for example random mutagenesis followed by adaptive laboratory evolution — run longer but often achieve improvements that neither method achieves alone. The project proposal includes a realistic timeline with defined milestones so you know what to expect at each stage before the campaign starts.

Classical strain improvement and genetic engineering are both used to improve microbial production strains, but they differ fundamentally in approach, regulatory outcome, and the type of knowledge required. Classical strain improvement uses non-recombinant techniques - random mutagenesis, adaptive laboratory evolution, and phenotypic selection, to generate genetic variation across the genome and select for variants with improved industrial performance. It does not require knowledge of the organism's genetics or biosynthetic pathways, and it produces strains that contain no recombinant DNA. Genetic engineering uses molecular biology tools, including CRISPR-Cas9, recombinant DNA, and targeted gene editing - to make specific, designed changes to the genome based on detailed knowledge of the metabolic network. It is more precise but produces organisms classified as GMOs under EU and in many cases US regulatory frameworks. Classical strain improvement is the preferred approach when regulatory status matters, for food, feed, and many pharma applications - or when the genetics of the production organism are not well characterised. Deltra Labs specialises in classical methods and does at the moment not use recombinant DNA techniques.

At minimum, a viable culture of your production strain. This can be provided as a frozen glycerol stock, a lyophilised culture, or an active culture on agar or in liquid medium, whichever is most practical for you to ship or transfer. We also ask for your current performance baseline: the titer, yield, productivity, or other metric you want to improve, measured under your current conditions. Any existing process data, fermentation records, or characterisation data is useful context but not required to start. We will evaluate the starting strain in-house at the beginning of the project and confirm the baseline before the mutagenesis campaign begins. A mutual NDA is signed before any biological material or data is shared.

Yes, and this is one of the primary reasons industrial food and feed companies choose classical strain improvement over genetic engineering. Under EU Directive 2001/18/EC, organisms produced by classical mutagenesis are explicitly exempted from GMO classification, provided no recombinant nucleic acid molecules are used. This exemption has been in place since the directive was adopted and has been consistently applied across the EU. In the United States, strains developed by classical mutagenesis are generally eligible for GRAS (Generally Recognized As Safe) notification, provided the production organism itself has a history of safe use.The range of industrially relevant traits that can be improved through classical methods is broad. In fermentation performance, common targets include improved oxygen transfer rate through reduced broth viscosity in filamentous fungi such as Aspergillus and Penicillium, increased titer and volumetric productivity of target compounds, and improved batch-to-batch consistency. In terms of product classes, classical strain improvement has been successfully applied to pigment production including carotenoids, astaxanthin, lycopene, and riboflavin; industrial enzymes such as proteases, lipases, amylases, cellulases, and phytases; organic acids including citric acid, lactic acid, itaconic acid, and succinic acid; amino acids such as lysine, glutamate, threonine, and valine; lipids and single-cell oils for food, feed, and oleochemical applications; vitamins including riboflavin (B2) and cobalamin (B12); biosurfactants and bioemulsifiers; and secondary metabolites such as antibiotics and antifungals. Stress tolerance is another well-established target area, covering increased tolerance towards low pH and organic acid accumulation, high salt and osmotic stress, elevated fermentation temperatures, solvent toxicity, and inhibitory product concentrations. Improvements in these traits directly reduce production costs and increase process robustness at industrial scale.Deltra Labs delivers the complete strain pedigree documentation required to support GRAS notifications and EU regulatory dossiers, including the mutagenesis treatment records, selection history, and stability data that regulators require to confirm the non-recombinant nature of the strain.

Both. We regularly work with proprietary industrial production strains that have already undergone years of previous improvement — either by classical methods, by metabolic engineering, or both. We also work with wild-type isolates and standard laboratory strains that are being developed into production organisms for the first time. Industrial production strains often start from a higher performance baseline, which means absolute improvement targets may be smaller, but the commercial value of each percentage point of improvement is typically much higher. We assess the current performance level and improvement potential during the feasibility call and design the campaign scope accordingly.

Pedigree documentation is the complete written record of every step taken to develop or improve a microbial strain, from the starting material through every mutagenesis treatment, selection round, and screening decision, to the final characterised improved strain. It is the strain's traceable history. A complete pedigree document includes: the identity, source, and baseline performance of the starting strain; the mutagenesis method, mutagen identity, dose or concentration, exposure time, and survival rate for each treatment round; the selection strategy and screening criteria applied at each round; the lineage of colonies selected for further rounds; the performance data at each selection stage; stability testing results demonstrating that the improved phenotype is maintained over successive generations; and the final strain characterisation including morphology, growth behaviour, and production performance. Pedigree documentation matters for three reasons. First, regulatory submissions - GRAS notifications, AMF dossiers, and EU food and feed approvals all require documented proof of how a strain was developed, including confirmation that no recombinant DNA was used. Second, IP protection - the pedigree is the legal paper trail that establishes when, how, and by whom a strain was developed. Third, internal quality assurance - larger industrial companies typically require a complete development history before an outsourced strain can be approved for use in their production processes. Deltra Labs delivers audit-ready pedigree documentation as a standard deliverable in every project.

Yes. This is one of the most common starting points for projects at Deltra Labs. Many clients come to us after reaching a performance plateau with their internal improvement programme — either because they have exhausted their in-house mutagenesis approaches, because they lack the screening throughput to run further rounds efficiently, or because they need an external perspective on why improvement has stalled. We review any available data from previous rounds before designing the campaign, which helps us avoid repeating approaches that have already been tried and focus on strategies with the best chance of achieving further improvement. Prior improvement history is valuable context, not an obstacle.

Random mutagenesis and adaptive laboratory evolution (ALE) are the two primary non-recombinant techniques used in classical strain improvement programmes. They are often discussed together and sometimes confused with each other, but they work through fundamentally different mechanisms, target different types of improvement, and are suited to different biological situations. Understanding the distinction helps in designing a campaign that achieves the target phenotype efficiently.Random mutagenesis — how it worksRandom mutagenesis uses a chemical or physical mutagen to introduce random mutations across the entire genome of a microbial population. The most commonly used mutagens are ultraviolet (UV) radiation, which introduces pyrimidine dimers that are repaired imperfectly and result in point mutations; ethyl methanesulfonate (EMS), an alkylating agent that causes G/C to A/T transitions across the genome; and N-methyl-N-nitro-N-nitrosoguanidine (NTG, also written MNNG), a highly potent chemical mutagen that introduces clustered mutations particularly around the replication fork. Each mutagen has a different mutation spectrum — the types and distribution of mutations it introduces — and the choice of mutagen is part of the campaign design.After mutagenesis treatment, the surviving population is screened for variants that express the desired phenotype at a higher level than the parent strain. The screening method is critical and varies by target trait. For titer improvement of an extracellular product, high-throughput plate-based assays can evaluate thousands of colonies rapidly. For intracellular products or traits that require fermentation to measure — productivity, oxygen transfer efficiency, broth rheology — the screening throughput is lower and the campaign takes longer. The selected improved variants are then typically subjected to further mutagenesis rounds in an iterative cycle until the target improvement is reached or a plateau is encountered.Random mutagenesis is well suited to targets where a large improvement is needed quickly, where the genetic basis of the trait is unknown, and where a high-throughput screening assay is available. It has historically been the workhorse of industrial strain improvement — the high-producing Penicillium chrysogenum strains that supply the global penicillin market, the Aspergillus niger strains used in citric acid production, the Corynebacterium glutamicum strains producing millions of tonnes of lysine annually, and many of the enzyme-producing Bacillus and Trichoderma strains used in detergent and food processing applications were all developed primarily through iterative random mutagenesis and selection campaigns.Adaptive laboratory evolution — how it worksAdaptive laboratory evolution (ALE) uses a fundamentally different principle. Rather than introducing mutations artificially, ALE applies a defined and sustained selective pressure to a microbial population over many generations and allows natural evolution — mutation, selection, and genetic drift — to generate and fix beneficial mutations. The organism adapts to the imposed pressure through the same evolutionary mechanisms that drive natural selection, but in a controlled laboratory environment and on a compressed timescale.The selective pressure in ALE is designed to match the target phenotype. For improving tolerance to a toxic substrate, inhibitory product, organic acid, solvent, or elevated temperature, the population is propagated under progressively increasing concentrations or severity of the stressor. Strains that grow better under the stressful condition outcompete those that do not, and beneficial mutations accumulate over successive transfers or continuous culture cycles. For improving growth rate on a non-preferred carbon source — for example, improving xylose utilisation in a yeast strain or methanol tolerance in Pichia pastoris — the population is propagated with that substrate as the sole carbon source, selecting for faster-growing variants over time.ALE is particularly well suited to complex, polygenic traits — phenotypes that are controlled by multiple genes simultaneously rather than a single enzymatic step — because natural evolution can navigate the interaction between multiple mutations in a way that rational engineering cannot easily replicate. Tolerance to ethanol, osmotic stress, low pH, high temperature, and inhibitory fermentation by-products are classic ALE targets. Growth rate improvement, substrate range expansion, and adaptation to non-standard media compositions are also well-established ALE applications.How they compare in practiceThe two methods differ in several practically important ways. Random mutagenesis produces results faster in terms of calendar time per round — a mutagenesis treatment, recovery, and screening cycle can be completed in four to eight weeks for a fast-growing bacterium. ALE typically requires weeks to months of continuous propagation before stable improved phenotypes emerge and can be reliably isolated. However, ALE often produces more stable improvements because the beneficial mutations have been fixed under sustained selective pressure rather than identified in a single screening event.Random mutagenesis generates the highest genetic diversity in the shortest time and is most effective when a high-throughput screening assay exists for the target phenotype. ALE generates targeted adaptation to a specific environmental condition and is most effective when the target is a complex, multi-gene phenotype that cannot easily be screened for in high throughput. For some projects, the most effective campaign combines both methods — random mutagenesis to generate initial diversity and break through an early plateau, followed by ALE to consolidate and extend the improvement under realistic process conditions.Both methods produce strains that contain no recombinant DNA and are not classified as genetically modified organisms under EU Directive 2001/18/EC or FDA guidelines, which is the defining regulatory advantage of the classical strain improvement approach over metabolic engineering and CRISPR-based methods.Which method does Deltra Labs use for your project?The choice between random mutagenesis, adaptive laboratory evolution, or a combination of both depends on the target phenotype, the organism's growth characteristics, the availability of a suitable screening assay, and the acceptable timeline. At Deltra Labs we assess these factors during the project scoping phase and design the campaign accordingly. For projects where both methods are applicable, we discuss the trade-offs with you and recommend the approach that best fits your timeline, budget, and target outcome. The project proposal includes the rationale for the chosen strategy so you understand why we are recommending the approach we are, not just what we plan to do.